USANA Health Sciences, Inc. (NYSE:USNA) Stock Holdings Lifted by Rhumbline Advisers

Rhumbline Advisers lifted its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 7.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,486 shares of the company’s stock after acquiring an additional 2,425 shares during the quarter. Rhumbline Advisers owned 0.19% of USANA Health Sciences worth $1,651,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Dimensional Fund Advisors LP lifted its holdings in shares of USANA Health Sciences by 3.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 677,664 shares of the company’s stock valued at $36,323,000 after purchasing an additional 21,524 shares during the last quarter. CWM LLC lifted its stake in USANA Health Sciences by 21.8% during the first quarter. CWM LLC now owns 1,543 shares of the company’s stock valued at $75,000 after buying an additional 276 shares in the last quarter. Panagora Asset Management Inc. lifted its stake in USANA Health Sciences by 143.1% during the second quarter. Panagora Asset Management Inc. now owns 28,881 shares of the company’s stock valued at $1,307,000 after buying an additional 16,999 shares in the last quarter. Allianz Asset Management GmbH boosted its holdings in shares of USANA Health Sciences by 43.0% in the fourth quarter. Allianz Asset Management GmbH now owns 26,970 shares of the company’s stock worth $1,446,000 after buying an additional 8,108 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in shares of USANA Health Sciences by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after acquiring an additional 494 shares in the last quarter. 54.25% of the stock is owned by institutional investors.

USANA Health Sciences Trading Down 3.9 %

Shares of NYSE USNA opened at $38.63 on Friday. USANA Health Sciences, Inc. has a one year low of $36.05 and a one year high of $60.90. The business has a 50-day moving average price of $40.90 and a two-hundred day moving average price of $44.45. The firm has a market capitalization of $735.94 million, a PE ratio of 12.03, a PEG ratio of 1.28 and a beta of 0.90.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.11). USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. The company had revenue of $212.87 million for the quarter, compared to analyst estimates of $218.64 million. During the same quarter in the prior year, the business posted $0.89 earnings per share. Research analysts anticipate that USANA Health Sciences, Inc. will post 2.5 EPS for the current year.

Insider Buying and Selling at USANA Health Sciences

In other news, Director John Turman Fleming sold 1,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total value of $44,430.00. Following the transaction, the director now directly owns 2,503 shares of the company’s stock, valued at $111,208.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Paul A. Jones sold 6,266 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Turman Fleming sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the sale, the director now directly owns 2,503 shares of the company’s stock, valued at $111,208.29. The disclosure for this sale can be found here. Insiders sold 7,940 shares of company stock valued at $311,670 in the last quarter. Company insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on USNA. DA Davidson decreased their price objective on shares of USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, July 25th. StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.